Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review

@article{Pardis2019ClozapineAT,
  title={Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review},
  author={Parnian Pardis and Gary Remington and Roshni Panda and Milan Lemez and Ofer Agid},
  journal={Journal of Psychopharmacology},
  year={2019},
  volume={33},
  pages={1187 - 1198}
}
Background: It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent. However, reports do indicate clozapine carries a liability for tardive dyskinesia. Aims: This review sought to evaluate clozapine in relation to tardive dyskinesia in the context of available evidence. Methods: Medline, Embase, and PsycINFO databases were searched for studies published in English, using the keywords… 

Figures and Tables from this paper

A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders

An overall effectiveness of clozapine in the treatment of TD for patients with a range of psychiatric conditions is suggested, suggesting different treatment protocols are required for different conditions.

SELECTED NEUROLOGIC AND PSYCHIATRIC OUTCOMES IN PATIENTS TREATED WITH CLOZAPIN (Review Article)

Clozapine is a second-generation antipsychotic mostly used for treatment-resistant schizophrenia and acute suicidality and it has various side effects which need to be promptly addressed, including neurological and psychiatric side effects.

Pathophysiology, prognosis and treatment of tardive dyskinesia

Patients who develop TD have poorer prognoses, worse health-related quality of life, greater social withdrawal and higher mortality than patients without TD, and Physicians should treat with antipsychotics only when necessary and at the lowest effective dose, and frequently monitor for TD symptoms.

A Low Clozapine Dose Improved Refractory Tardive Dystonia without Exacerbating Psychiatric Symptoms: A Case Report

A 41-year-old female with schizophrenia and TD who was treated with a low clozapine dose improved refractory TD and further ameliorated psychiatric symptoms.

A new era in the diagnosis and treatment of tardive dyskinesia.

  • S. Caroff
  • Psychology, Medicine
    CNS spectrums
  • 2022
Questions remain for future research including the mechanisms underlying TD, genetic predisposition, phenomenological diversity, whether new cases are reversible, how to implement best practices to prevent and treat TD, and whether the development of novel antipsychotics free of the risk of TD is attainable.

“Evaluating and Managing Tardive Dyskinesia in the Older Adult”

The stepwise management approach starts by frequent monitoring, discontinuing the culprit antipsychotic, decreasing the dose otherwise; followed by switching to less potent antipsychotics and prescribing VMAT-2 inhibitors.

Management of Tardive Syndrome: Medications and Surgical Treatments

  • S. Factor
  • Medicine, Psychology
    Neurotherapeutics
  • 2020
The discussion will start with switching antipsychotics and the use of clozapine monotherapy which, despite the lack of higher-level evidence, should be considered for the treatment of psychosis and TS.

Tardive syndromes

Tardive syndromes, denoting the delayed onset of movement disorders following administration of dopamine receptor-blocking drugs, have diverse manifestations ranging from the classic oro-bucco-lingual dyskinesia, through dystonic craniocervical and trunk posturing, to abnormal breathing patterns.

A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology

Rational use requires modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, the use of clozAPine levels for personalizing dosing, and theUse of slow and personalized titration to make clozabine as safe as possible and contribute to increased life expectancy and well-being.

The Modernization of Clozapine

There is an urgent need for advancing technology used for clozapine monitoring, evaluating barriers created by REMS, and establishing consistent practices throughout the US.

References

SHOWING 1-10 OF 89 REFERENCES

Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.

The overall results show that clozapine treatment can yield a slight reduction in TD and support that a switch to clozAPine should be considered for patients with moderate to severe TD and/or patients who experience substantial discomfort due to TD.

Does clozapine cause tardive dyskinesia?

If cases do develop, the risk of tardive dyskinesia is likely to be less with clozapine than with typical neuroleptics, and if cases do development, therisk of tARDive dysKinesia will be less than with traditional neuroleptic patients.

Clozapine and tardive dyskinesia: analysis of clinical trials

Clozapine in tardive dyskinesia: observations from human and animal model studies.

The data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.

A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.

Quetiapine effectively reduces the severity of tardive dyskinesia and is well tolerated in patients with established tardives dyskinese and is effective in treating patients with developed schizophrenia or schizoaffective disorder.

Tardive dyskinesia, clozapine, and treatment response

Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug

  • Chun-Rong LiYoung-Chul Chung I. Hwang
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2009
The results suggest that clozapine may cause tardive dyskinesia, however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort.

Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.

Relatively low doses of clozapine are effective for the treatment of neuroleptic-induced extrapyramidal syndromes in chronic schizophrenic patients, and the relief of tardive dyskinesia, parkinsonism, and chronic akathisia in this group of patients occurs more rapidly than the reduction in psychotic symptoms.

Tardive dyskinesia: eliminated, forgotten, or overshadowed?

  • G. Remington
  • Psychology, Medicine
    Current opinion in psychiatry
  • 2007
The limited evidence available clearly indicates that the atypical antipsychotics have a decreased liability of tardive dyskinesia, approximately 1% compared with 5% for typical agents annually.

Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy

The development of clozapine-induced microseizures, orofacial dyskinesia, and stuttering in a 17-year-old adolescent male with treatment of refractory early onset schizophrenia on clozAPine and concurrent lithium therapy is reported on.
...